DOCSLIB.ORG

Building a Better Carefusion

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Building a Better Carefusion Building a better CareFusion Annual Report 2014 Dear Shareholders, Customers and Employees: Five years ago, CareFusion was born out of a new Pyxis® ES dispensing platform, our Medical spinoff from Cardinal Health, with the vision Systems segment had a very strong fourth quarter, to improve the safety and cost of healthcare with 20 percent revenue growth and 16 percent for generations to come. adjusted segment profit† growth compared to What we have accomplished in less than the prior year. We also had record committed 2,000 days has required discipline and hard contracts for both our Dispensing Technologies work, and the results are now visible inside and Infusion Systems business lines and have a our company and becoming clearer to our record backlog to fuel top-line growth in the customers and our shareholders. The launch coming year. of the company started in three phases: The We have been active on the M&A front. In fiscal Stand-Up phase consisted of separating from 2014, we completed our largest acquisition to Cardinal Health and creating an independent, date: the $500 million tuck-in of GE Healthcare’s publicly traded company. Next came the Building Vital Signs business. In addition, we acquired a Foundation phase where we started to reshape Sendal in Spain to expand our infusion disposables the portfolio of businesses through both business and made a strategic investment in acquisitions and divestitures. And finally, the Caesarea Medical Electronics (CME) to broaden stage we are in now, which is Accelerating our understanding of a different segment of the for Long-Term Growth. infusion market. Along the way, we’ve acquired eight companies, We continued to generate healthy cash flows, expanded globally and built CareFusion into including $685 million of operating cash flow one of the top brands in the medical technology during the year. Our balance sheet remains strong, industry. We’ve introduced more than 60 new as does our ability to leverage it for additional products, awarded more than $1 million in strategic acquisitions. Clinical Excellence Grants and touched millions We have already deployed approximately of patients’ lives. $700 million for M&A as part of our three-year And today, we are in a strong position. Fiscal plan, which is in addition to the $1.1 billion 2014 ended as a solid year across CareFusion, we have used for share repurchases. Capital with above-market organic revenue growth deployment will remain an important part of across the majority of our businesses and our plans to create shareholder value. 11 percent growth in our adjusted earnings Fiscal 2014 also saw the fruits of our continued † per share from continuing operations. These investment in research and development. results were led by double-digit top- and We launched more than 20 new products, bottom-line growth from our Procedural Solutions including our Pyxis ES platform and complete segment, marking eight consecutive quarters of medication management solution; several line positive momentum. After an expected slow start extensions to our ChloraPrep® franchise; and to the year because of delays in ramping up our new infusion disposable products, including our Chemo Safety System. The R&D used to fuel digits, adjusted operating margins† to expand to these introductions was funded by savings from 23 percent or greater, and adjusted earnings our work to simplify the company and build a per share from continuing operations† to grow foundation for growth. 10 percent to 12 percent. We plan to deploy at We continued to position our team for success least 50 percent of our free cash flow for share as healthcare consolidates in the U.S. and adapts buybacks and tuck-in acquisitions. Larger-scale to cost pressures in other geographies. We are acquisitions are excluded from this outlook strengthening how we go to market in our selling because of their unpredictable nature, but we organizations, investing in our service organization remain steadfast in our commitment to gain and building scale in our core businesses. We also scale, grow outside the U.S. and improve our remain focused on the projects we have underway strategic portfolio of products through mergers across the company to simplify CareFusion, expand and acquisitions. We continue to actively manage our margins and improve the experience we a pipeline of opportunities ranging in all sizes, deliver for our customers. because we view this as an important lever for our growth. And we leveraged the strength of our CareFusion brand with new strategies that cut across business As we grow CareFusion, we will build on our past lines. From our new enterprise-wide medication accomplishments while we generate new ways to management solution to our CareFusion Focus on serve our global customers, simplify our business Quality Care initiative, we are seeing the benefits and enhance the experience we deliver. We have we can bring customers when we support them as built a culture focused on innovation, continuous CareFusion—working across business lines, rather improvement and not mistaking effort for results. than as standalone product lines. We will continue to work on being more flexible to evolve with our dynamic industry and continue To continue our success, we need to stay to lead in patient safety, quality and helping our nimble—change how we sell and who we sell to customers reduce their costs. We’ve come a long so our customers can meet their goals of doing way in five years and we have a long runway more with less, while still keeping patients safer ahead, but we’re just getting started. than ever before. This will drive us through fiscal 2015 and beyond. When we turn to next year, we expect revenue Sincerely, growth of 5 percent to 7 percent, adjusted operating margins† to be 20.5 percent to 21.5 percent for the full year, and adjusted earnings per share from continuing operations† to be in the range of $2.60 to $2.75, representing Kieran T. Gallahue 10 percent to 17 percent growth from fiscal 2014. Chairman and Chief Executive Officer Looking beyond and through fiscal 2017, we expect annual revenue growth in the mid-single GAAP Reconciliations (in millions, except per share amounts) Restructuring Amortization Step-up of Reserve for and Acquistion of Acquired Acquired Expected Gov’t GAAP Integration Intangibles Inventory Settlement Adjusted Fiscal 2015 Guidance A Diluted EPS from continuing operations $2.15-$2.30 $0.21 $0.23 $0.01 - $2.60-$2.75 Fiscal 2014 Revenue $3,842 - - - - $3,842 B Income from continuing operations $417 $30 $48 $8 - $503 A Diluted EPS from continuing operations $1.96 $0.14 $0.23 $0.04 - $2.36 Diluted shares outstanding 212.9 - - - - 212.9 Q4 Fiscal 2014 Segment profit—Medical Systems $146 $2 $10 - - $158 Segment profit—Procedural Solutions $48 $7 $11 $3 - $69 Fiscal 2013 Revenue $3,550 - - - - $3,550 B Income from continuing operations $389 $14 $39 - $33 $475 A Diluted EPS from continuing operations $1.74 $0.06 $0.17 - $0.15 $2.12 Diluted shares outstanding 224.0 - - - - 224.0 Q4 Fiscal 2013 Segment profit—Medical Systems $124 $3 $9 - - $136 Segment profit—Procedural Solutions $46 $1 $6 - - $53 A. Earnings per share calculations are performed separately for each component presented. Therefore, the sum of the per share components from the table may not equal the per share amounts presented. For fiscal 2015 guidance, restructuring and integration impact on diluted earnings per share is based on a mid-point of an estimated range of $0.19 to $0.23 per diluted share. B. Adjusted income from continuing operations is presented net of tax effect. References and endnotes † Denotes non-GAAP financial measure. These non-GAAP financial measures exclude amortization of acquired intangibles and nonrecurring items related to restructuring and acquisition integration charges. Commencing with the quarter ended December 31, 2013, the company began excluding from its adjusted results inventory valuation step-up charges from acquisitions. Financial information for historical periods has not been revised to reflect the exclusion of such inventory step-up charges, as the amounts were immaterial. For the fiscal year ended June 30, 2013, adjusted financial measures also exclude the reserve for the expected government settlement, which we paid in January 2014. See reconciliations above. Note: A full GAAP to non-GAAP reconciliation can be found in our earnings release that reported results for the quarter and fiscal year ended June 30, 2014, which was furnished to the United States Securities and Exchange Commission on our Current Report on Form 8-K on August 7, 2014, and is posted on our website at www.carefusion.com under the Investors tab. The Form 8-K also includes a discussion of the reasons why management believes that the presentation of non-GAAP financial measures provides useful information to investors regarding our financial condition and results of operations. Senior leadership Kieran T. Gallahue Gordon LaFortune Michael Paolucci Chairman and Executive Vice President Executive Vice President Chief Executive Officer EMEA/ANZ Commercial Operations Human Resources and and Global Infusion Disposables Chief Human Resources Officer Jim Hinrichs Chief Financial Officer Tom Leonard Joan Stafslien President Executive Vice President Don Abbey Medical Systems General Counsel and Executive Vice President Corporate Secretary Quality, Regulatory and Jim Mazzola Medical Affairs Senior Vice President Michael Zill Global Marketing and Communication Executive Vice President Scott Bostick Chief Information Officer Senior Vice President Michael Meyerhoff Americas Commercial Operations Vice President Asia Commercial Operations Ron Frisbie Executive Vice President Dr. Carlos M. Nunez Global Operations Chief Medical Officer Board of Directors Kieran T. Gallahue Jacqueline B. Kosecoff, PhD (A) Michael D. O’Halleran (H) Chairman and CEO Managing Partner Senior Executive Vice President CareFusion Corporation Moriah Partners, LLC Aon PLC Supratim Bose J.
Load more

Recommended publications
  • Cardinal Health 2019 Annual Report
    2019 Annual Report Essential to care ™ Corporate Offices Cardinal Health 7000 Cardinal Place Dublin, Ohio 43017 614.757.5000 www.cardinalhealth.com © 2019 Cardinal Health. All Rights Reserved. CARDINAL HEALTH, the Cardinal Health LOGO and ESSENTIAL TO CARE are trademarks of Cardinal Health and may be registered in the US and/or in other countries. All other marks are the property of their respective owners. Lit. No. 5CR19-971925 (08/2019) DearDear fellow fellow shareholders: shareholders: CorporateCorporate and and In myIn my letter letter to toyou you last last year, year, I acknowledged I acknowledged investorinvestor information information thethe trust trust you you place place in usin usto torun run the the business business CorporateCorporate offices offices FinancialFinancial information information effectivelyeffectively and, and, in inturn, turn, be beresponsible responsible CardinalCardinal Health Health ComprehensiveComprehensive financial financial and andother other information information about about stewardsstewards of ofyour your capital. capital. I’d I’dlike like to toshare share with with 70007000 Cardinal Cardinal Place Place CardinalCardinal Health Health can can be obtainedbe obtained by visiting by visiting the theInvestor Investor Dublin,Dublin, Ohio Ohio 43017 43017 RelationsRelations page page at ir.cardinalhealth.com. at ir.cardinalhealth.com. youyou some some of ofour our accomplishments accomplishments over over 614.757.5000614.757.5000 thethe past past year year and and where where we we are are going going
    [Show full text]
  • Catalent, Inc. Annual Report 2019
    Catalent, Inc. Annual Report 2019 Form 10-K (NYSE:CTLT) Published: August 27th, 2019 PDF generated by stocklight.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________ FORM 10-K ______________________________ x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2019 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36587 ___________________________ CATALENT, INC. (Exact name of registrant as specified in its charter) ______________________________ Delaware 20-8737688 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 14 Schoolhouse Road 08873 Somerset, New Jersey (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (732) 537-6200 ______________________________ Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 par value per share CTLT New York Stock Exchange Securities registered pursuant to Section 12(g) of the Act: None ______________________________ Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes x No o Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes o No x Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Cardinal Health 2018 Proxy Statement
    2018 Proxy Statement Notice of Annual Meeting of Shareholders Letter to Cardinal Health Shareholders 1 Notice of Annual Meeting of Shareholders 3 Proxy Summary 4 Fiscal 2018 Highlights 4 Governance and Board Highlights 4 Our 2018 Board Nominees 5 Addressing the Opioid Crisis 6 Attending the Annual Meeting of Shareholders 8 Roadmap to Voting Matters 8 How to Vote 8 Corporate Governance 9 Proposal 1 — Election of Directors 9 Board Membership Criteria: What we look for 9 Our Director Nominees 9 Our Board’s Composition and Structure 15 Our Board’s Primary Role and Responsibilities and Processes 19 Shareholder Engagement 21 Director Compensation 22 Related Person Transactions Policy and Process 23 Audit Committee Matters 24 Proposal 2 — Ratification of Appointment of Ernst & Young LLP as Independent Auditor 24 Audit Committee Report 24 Fees Paid to Ernst & Young LLP 25 Policy on Pre-Approval of Services Provided by Ernst & Young LLP 25 Executive Compensation 26 Proposal 3 — Advisory Vote to Approve the Compensation of Our Named Executive Officers 26 Compensation Discussion and Analysis 27 Human Resources and Compensation Committee Report 34 Executive Compensation Tables 35 Pay Ratio Disclosure 48 Shareholder Proposals 49 Proposal 4 — Shareholder Proposal on a Policy to Not Exclude Legal and Compliance Costs for Purposes of Determining Executive Compensation 49 Proposal 5 — Shareholder Proposal on the Ownership Threshold for Calling a Special Meeting of Shareholders 51 Share Ownership Information 52 Beneficial Ownership 52 Compliance with Section 16(a) of the Exchange Act 53 Other Matters 54 General Information About the Annual Meeting of Shareholders 54 Communicating with the Board 56 Shareholder Recommendations for Director Nominees 56 Submitting Proxy Proposals and Director Nominations for the Next Annual Meeting of Shareholders 56 Corporate Governance Guidelines 57 Transfer Agent 57 Other Information 57 Annex A — Use of Non-GAAP Financial Measures 58 strong leadership and commitment to Cardinal Health during his Letter to Cardinal tenure.
    [Show full text]
  • Cardinal Health, Inc. (Exact Name of Registrant As Specified in Its Charter)
    Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2016 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 1-11373 Cardinal Health, Inc. (Exact name of registrant as specified in its charter) Ohio 31-0958666 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) 7000 Cardinal Place, Dublin, Ohio 43017 (Address of principal executive offices) (Zip Code) (614) 757-5000 (Registrant’s telephone number, including area code) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.
    [Show full text]
  • 2008 Annual Report
    essential to care Annual Report 2008 In today’s complex world of healthcare, safe and efficient care is not optional. It is essential. At Cardinal Health, we work with hospitals and pharmacies across the globe every day to improve the safety and productivity of the care they provide. Long before a patient arrives at a hospital for treatment or calls a pharmacy for a prescription, Cardinal Health is an essential part of delivering safe and eff icient care. We provide the medical technologies that help ensure safe doses of critical medications at the bedside. Our surgical gloves help protect both caregivers and patients from infections. We deliver medicine to pharmacies, so it is ready to be dispensed at a moment’s notice. These are just a few examples of how Cardinal Health is essential to care. But it is not enough to provide the products and services that are essential in today’s healthcare system. At Cardinal Health, essential to care means: Caring about our customers. Caring about patient outcomes. Caring about employees. Caring about shareholders. Caring about our communities. Essential to care. It is the driving force behind Cardinal Health’s mission of making healthcare safer and more productive. Chairman’s letter To our customers, employees and shareholders: In the United States and around the world, the cost of to do: help sick patients get better. That’s why we believe delivering healthcare continues to accelerate. I believe that that no company is better positioned than Cardinal Health one of the keys to driving a meaningful reduction in the cost to streamline the healthcare supply chain, help clinicians of care is improving the quality of care.
    [Show full text]
  • Cardinal Health 2020 Annual Report
    2020 Annual Report Dear fellow shareholders, A year ago, I closed my letter to you with a reflection on our role in healthcare. Over the past several months, we have seen that now more than ever, what we do matters — to our customers, to the patients they serve, and to our communities. In my nearly 30 years as part of the Cardinal Health family, I have experienced significant transformation, both within our company and within the healthcare industry. We have expanded our products, services and markets, evolved with technological and regulatory changes, and adapted in the face of external challenges. In each of these moments, we have demonstrated agility and embraced change to emerge as a stronger company with an even more solidified role in healthcare. Now, as we navigate the unprecedented challenges of a global pandemic, we are leaning on that legacy of adaptability and dedication. In fiscal 2020, we delivered on our commitments and continued to execute on our long-term strategic priorities, all as we adapted our operations to address the unique challenges presented by COVID-19. Our fiscal 2020 financial performance Across the company, in fiscal 2020, we demonstrated positive In the Medical segment, our cost savings initiatives, performance despite significant global challenges. We grew particularly within our global manufacturing and supply non-GAAP operating earnings, exceeded our non-GAAP chain, drove significant benefits throughout the year. We EPS guidance range, surpassed our cost savings target, and expect these workstreams to continue to deliver greater strengthened our balance sheet. In the year, we invested $375 efficiencies and additional value into the future.
    [Show full text]
  • Corporate Citizenship Report 2019 Table of Contents
    Corporate Citizenship Report 2019 Table of contents Editor’s note: This report was largely created before the COVID-19 pandemic. During the pandemic, we at Cardinal Health are working around the clock to meet the needs of healthcare providers so they can safely serve the patients who depend on them. Learn about our response » A message to our stakeholders ______________________________ 3 Creating value for our customers and our partners ����������27 Essential to care™ _________________________________________ 7 Strengthening our communities _________________________41 Our Path Forward ________________________________________ 8 Operating sustainably and responsibly ____________________48 ESG management and governance __________________________ 9 Governance and ethics _________________________________56 Stakeholder engagement _________________________________ 11 About this report _______________________________________ 63 Empowering our people ________________________________ 12 GRI index _____________________________________________ 64 Table of contents Our people Customers and partners Our communities Sustainability Governance GRI index 2019 Corporate Citizenship Report | 2 A message to our stakeholders This Corporate Citizenship Report was nearly complete when the COVID-19 pandemic changed the world in ways no one could ever have imagined. So I am beginning this letter differently than I originally planned. First, I want to express my deepest gratitude to every frontline worker and healthcare professional around the globe. The courage and commitment you bring to work with you every day is awe-inspiring. Your work is making a difference. Thank you. Since early March, the 48,000 Cardinal Health employees around the we have significantly expanded our technology infrastructure to help world have been more focused than ever before on delivering the employees around the globe continue to support customers, patients products and solutions that improve the lives of people every day.
    [Show full text]
  • Distributors New York Settlement Agreement
    DISTRIBUTORS NEW YORK SETTLEMENT AGREEMENT Table of Contents I. Overview ......................................................................................................................1 II. Definitions ....................................................................................................................1 III. Condition to Effectiveness of Agreement ..................................................................12 IV. Participation by Subdivisions .....................................................................................12 V. Settlement Payments ..................................................................................................14 VI. Allocation and Use of Settlement Payments. .............................................................26 VII. Enforcement ...............................................................................................................27 VIII. Plaintiffs’ Attorneys’ Fees and Costs .........................................................................27 IX. New York Additional Restitution Amount ................................................................30 X. Release ........................................................................................................................30 XI. Later Litigating Subdivisions .....................................................................................34 XII. Reductions/Offsets .....................................................................................................38 XIII. Injunctive Relief
    [Show full text]
  • Pharma Services Q2 2019
    June 2019 CDMO – Transaction Comps CDMO - Transaction Comps USD in millions Announced Geographic EV / LTM EV / LTM Date Target Target Description Buyer Location Enterprise Value LTM Revenue LTM EBITDA Revenue EBITDA Operates as a CDMO that focuses on the development and Apr-19 Paragon Bioservices1 Catalent Pharma Solutions USA $1,200.0 $101.0 $56.0 11.9x 21.4x manufacturing of biopharmaceuticals Biogen (Denmark) Biopharmaceutical CDMO facility with 90,000L biologic Fujifilm Diosynth Mar-19 Denmark 890.0 NA NA NA NA Manufacturing Facility production capacity Biotechnologies Mar-19 Brammer Bio CDMO developing and manufacturing cell and gene therapies Thermo Fisher USA 1,700.0 NA NA NA NA CDMO offering services including analytical testing, API and Nov-18 Avista Pharma Solutions2 drug product development, early stage discovery, and Cambrex Corporation USA 252.0 65.0 NA 3.9x NA microbiology testing support Operates as a custom manufacturer of APIs and registered Jul-18 AMPAC Fine Chemicals3 SK Holdings USA 455.0 200.0 NA 2.3x NA intermediates for the pharmaceutical industry Provides contract development and manufacturing services in Jul-18 Halo Pharma Cambrex Corporation USA 425.0 105.0 27.0 4.0x 15.7x various dosage forms and drug delivery platforms Provides contract development and manufacturing services to Sep-17 Cook Pharmica Catalent Pharma Solutions USA 950.0 177.8 NA 5.3x NA pharmaceutical and biopharmaceutical companies Provides drug discovery and development services, as well as Jul-17 Aptuit Evotec USA 300.0 92.9 11.6 3.2x 25.8x
    [Show full text]
  • State Ex Rel. Jennings V. Purdue Pharma LP, Not Reported in Atl. Rptr
    State ex rel. Jennings v. Purdue Pharma L.P., Not Reported in Atl. Rptr. (2019) 2019 WL 446382 L.P. & The Purdue Frederick Company (“Purdue Pharma”). 2019 WL 446382 Only the Westlaw citation is currently available. Michael P. Kelly, Esq., Steven P. Wood, Esq., Daniel J. Brown, Esq., Hayley J. Reese, Esq., McCarter & English, UNPUBLISHED OPINION. CHECK Wilmington Delaware; John A. Freedman, Esq. (Argued), COURT RULES BEFORE CITING. Arnold & Porter Kay Scholer LLP, Washington, District Superior Court of Delaware. of Columbia; Sean O. Morris, Esq., Arnold & Porter Kay Scholer LLP, Los Angeles, California, Attorneys for STATE of Delaware, EX REL. Kathleen JENNINGS, Defendant Endo Pharmaceuticals, Inc. & Endo Health Attorney General of the State of Delaware, Plaintiff, Solutions, Inc. (“Endo”). v. Kevin B. Collins, Esq., Katherine B. Shaffer, Esq., PURDUE PHARMA L.P.; Purdue Pharma Covington & Burling, Washington, District of Columbia; Inc.; The Purdue Frederick Company; Endo Neil K. Roman, Esq., Covington & Burling, New York, Health Solutions Inc.; Endo Pharmaceuticals New York; A. Thompson Bayliss, Esq., Michael A. Inc.; McKesson Corporation; Cardinal Health Barlow, Esq. (Argued), Sarah E. Delia, Esq., David Inc.; AmerisourceBergen Corporation; A. Seal, Esq., Daniel J. McBride, Esq., Abrams & Anda Pharmaceuticals, Inc.; H.D. Smith, Bayliss, Wilmington, Delaware, Attorneys for Defendant LLC; CVS Health Corporation; and McKesson Corporation. Walgreens Boots Alliance, Inc., Defendants. David A. Felice, Esq., Bailey & Glasser LLP, Wilmington, C.A. No. N18C-01-223 MMJ CCLD Delaware; Steven Pyser, Esq., Ashley W. Hardin, Esq. | (Argued), Joshua D. Tully, Williams & Connolly, Submitted: November 15, 2018 Washington, District of Columbia, Attorneys for | Defendant Cardinal Health, Inc. Decided: February 4, 2019 Jennifer C.
    [Show full text]
  • Since 1895. Member SIPC and NYSE. Securities Products And
    Piper Jaffray Health Care Group Issue 229: May 24, 2004 Sections: Weekly Relative Price Performance Initial Public Offerings Subsequent Offerings Buyers & Sellers Movers & Shakers Index Performance Medical Technology Contacts Animas Prices 4.25 Million Shares at $15 Per Share in IPO May 19, 2004: Medical device maker Animas priced 4.25 million shares at $15 per share in its initial public offering which represented the top end of the filing range. The company, which makes insulin pumps for diabetics, originally filed to offer shares at an estimated price range of $13 to $15 a shares. Animas traded well in the public markets by closing up 18% after its first day of trading. Piper Jaffray and J.P. Morgan acted as co-lead advisors with Thomas Weisel Partners LLC acting as a co-manager on the deal. Animas, based in West Chester, Pennsylvania, has listed its stock on the Nasdaq under the symbol "PUMP." Cardinal Health to Buy Alaris May 19, 2004: Cardinal Health Inc. has agreed to acquire Alaris Medical Systems for $1.6 billion to expand beyond drug wholesaling and into medication safety products, the companies said on Wednesday. Including assumption of Alaris debt by Cardinal, the deal is worth $2 billion, the companies said. The deal fits with Cardinal's strategy of broadening its reach beyond shipping products between drug makers and pharmacies and hospitals. Cardinal produces pharmacy automation equipment and medical supplies and also provides packaging and marketing services for drug makers. Alaris makes medication safety systems such as computers that monitor patient safety during intravenous injections.
    [Show full text]
  • Carefusion Corporation (Exact Name of Registrant As Specified in Its Charter)
    As filed with the Securities and Exchange Commission on March 31, 2009 File No. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10 GENERAL FORM FOR REGISTRATION OF SECURITIES Pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934 CareFusion Corporation (Exact name of Registrant as specified in its charter) Delaware 26-4123274 (State or other jurisdiction of (I.R.S. employer incorporation or organization) identification number) 3750 Torrey View Court, San Diego, CA 92130 (Address of principal executive offices) (Zip Code) (858) 617-2000 (Registrant’s telephone number, including area code) Securities to be registered pursuant to Section 12(b) of the Act: Title of Each Class to be so Registered Name of Each Exchange on which Each Class is to be Registered Common Stock, par value $0.01 per share New York Stock Exchange Securities to be registered pursuant to Section 12(g) of the Act: None CAREFUSION CORPORATION INFORMATION REQUIRED IN REGISTRATION STATEMENT CROSS-REFERENCE SHEET BETWEEN INFORMATION STATEMENT AND ITEMS OF FORM 10 Certain information required to be included herein is incorporated by reference to specifically identified portions of the body of the information statement filed herewith as Exhibit 99.1. None of the information contained in the information statement shall be incorporated by reference herein or deemed to be a part hereof unless such information is specifically incorporated by reference. Item 1. Business. The information required by this item is contained under the sections of the information statement entitled “Information Statement Summary,” “Business” and “Our Relationship with Cardinal Health Following the Distribution.” Those sections are incorporated herein by reference.
    [Show full text]